Diabetes care at Abbott Laboratories has returned to sales growth as ex-U.S. sales of its new FreeStyle Libre kick in and the impact of diabetes device reimbursement reductions dropped off the books. The continuous glucose monitor eliminates regular finger sticks and has surpassed the company's sales expectations.
With Januvia contributing billions in critical revenue, Merck has backed its fair share of diabetes education and awareness efforts. But with its latest, the company may give vaccine sales a boost, too.
Abbott announced FDA clearance of its FreeStyle Precision Neo Blood Glucose Monitoring System as an over-the-counter product, and said it is the cheapest device in the diabetes meter and test strips arena.
Johnson & Johnson's SGLT2 inhibitor Invokana (canagliflozin)--among a handful of drugs in the new category of DPP-4 drugs for diabetes--not only took a big jump in sales for the first quarter but also made some significant market-share gains.
Johnson & Johnson's device strategy of divesting its worst performing businesses--while pushing forward with the rollout of innovative products--has yet to pay off. But the company is hopeful that it can return the business to sales growth over the next year.
Medtronic snatched up artificial pancreas technology from Israel-based DreaMed Diabetes for its insulin pumps, the company's latest deal as it looks to diversify its diabetes offerings and cash in on a growing market.
Med tech company executives often talk about the need to provide not just products but "solutions" to problems like meeting Affordable Care Act metrics at hospitals and lowering the cost of patient care. Now, Medtronic is expanding its push into healthcare services to a new front with the acquisition of the Netherlands' diabetes and research clinic Diabeter.
Gelesis has raised $22 million to support an ongoing 6-month trial of its first-generation weight loss capsule, Gelesis100. The company recently started the study to assess its impact on body weight and glycemic control. This data could be sufficient to gain a CE mark, the company expects.
To transport a hunger-suppressing molecule to the gut as a treatment for obesity, researchers at Vanderbilt University have put bacteria to work. The bacteria become lodged in the digestive system and release the lipid for up to a year at a time, altering the gut microbiome to stave off weight-related problems like diabetes and heart disease.
Study: U.S. healthcare reform has led to a diabetes diagnosis surge in states with Medicaid expansion
The enactment of the Affordable Care Act with its expansion of Medicaid benefits has led to an uptick in diabetes diagnoses by almost one-quarter, according to a study of deidentified test results from Quest Diagnostics. That's in states that opted to expand Medicaid under the new law during the first 6 months of 2014 as compared to the first 6 months of 2013.